{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382825894156423944.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Vivien N. Jacobs"}],"foaf:familyName":[{"@value":"Jacobs"}],"foaf:givenName":[{"@value":"Vivien N."}]}],"career":[{"institution":{"notation":[{"@value":"1Oncology Innovative Medicines and"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825894156423936","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1158/2159-8290.cd-14-0337"},{"@type":"URI","@value":"https://aacrjournals.org/cancerdiscovery/article-pdf/4/9/1046/1838210/1046.pdf"}],"notation":[{"@value":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1158/2159-8290.cd-14-0337_CaQBKA6bs95GD4mlQBA3Wefv4qN"}]}